Vera Therapeutics Revenue and Competitors

Location

#9351

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Vera Therapeutics's estimated annual revenue is currently $5.7M per year.(i)
  • Vera Therapeutics's estimated revenue per employee is $40,964
  • Vera Therapeutics's total funding is $188.9M.

Employee Data

  • Vera Therapeutics has 140 Employees.(i)
  • Vera Therapeutics grew their employee count by 122% last year.

Vera Therapeutics's People

NameTitleEmail/Phone
1
Chief Accounting OfficerReveal Email/Phone
2
CEOReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Chief Business OfficerReveal Email/Phone
5
Chief Operating OfficerReveal Email/Phone
6
Chief Development OfficerReveal Email/Phone
7
Chief Legal OfficerReveal Email/Phone
8
SVP and Head BiometricsReveal Email/Phone
9
SVP Medical AffairsReveal Email/Phone
10
VP, Head LegalReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M50%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M4-50%N/AN/A
#6
$0.7M80%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1731%N/AN/A
Add Company

What Is Vera Therapeutics?

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases that improve patients' lives.

keywords:N/A

$188.9M

Total Funding

140

Number of Employees

$5.7M

Revenue (est)

122%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vera Therapeutics News

2022-04-19 - Head-To-Head Analysis: Vera Therapeutics (VERA) and Its ...

Vera Therapeutics (NASDAQ:VERA – Get Rating) is one of 937 publicly-traded companies in the “Pharmaceutical preparations” industry,...

2022-04-17 - Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus ...

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Rating of “Buy” by Analysts. Posted by admin on Apr 19th, 2022.

2022-04-17 - Vera Therapeutics, Inc. Expected to Post Q1 2022 Earnings of ...

Wedbush has a “Outperform” rating and a $32.00 price objective on the stock. Wedbush also issued estimates for Vera Therapeutics' Q2 2022...

2021-04-20 - Vera Therapeutics Appoints Industry Veteran Dr. Celia Lin as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ -- Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Celia Lin, MD, as ...

2021-01-19 - Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 /PRNewswire/ -- Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP. Ot ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$37.1M14254%N/A
#2
$23.7M14524%$10.8M
#3
$59.4M148-4%N/A
#4
$66.2M150-4%$345.4M
#5
$76.7M154-8%$420.4M